Rotigotine extended release - Luye Pharma Group

Drug Profile

Rotigotine extended release - Luye Pharma Group

Alternative Names: LY-03003; Rotigotine extended release microspheres

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luye Pharma Group
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 12 Mar 2018 China Food and Drug Administration exempts rotigotine extended release from phase II trials in Parkinson's disease
  • 15 Feb 2018 US FDA exempts rotigotine extended release from phase II trials in Parkinson's disease
  • 08 Feb 2018 Luye Pharma Group has patent protection for rotigotine extended release in USA, China, Japan, Korea and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top